While biotech continues to reign supreme in the Boston tech sector, several other industries proved their mettle by securing hefty venture capital raises last month. Companies in SaaS, infrastructure and metal manufacturing sectors had some of the highest funding sums last month. Read on to find out how they’re using the fresh funds to fuel growth.
Top Boston Tech Funding Rounds, January 2024
- Accent Therapeutics
- Digital Onboarding
- Ratio Therapeutics
- SmartLabs
- Boston Metal
#5. $20 million, January 30
Boston Metals is working to decarbonize steelmaking with its electric tonnage metals technology platform. The company secured a $20 million Series C2 funding round from Marunouchi Innovation Partners to expand its presence in Asia. The round brings Boston Metal’s total funding to date to $282 million.
#4. $48 million, January 18
SmartLabs offers an integrated solution that allows companies to purchase R&D infrastructure and manufacturing solutions. Its Series C round saw participation from investors such as ArrowMark Partners and Winslow Capital Management. The funds will help SmartLabs expand and optimize its portfolio of laboratory solutions.
#3. $50 million, January 17
Pharmaceutical innovator Ratio Therapeutics announced a Series B funding round from investors like the Center for Technology Licensing at Cornell University. The company plans to invest its new funding to develop a therapy for treating and monitoring various solid-tumor cancers.
#2. $58 million, January 18
SaaS company Digital Onboarding secured a $58 million round of funding from Volition Capital. It offers financial institutions digital engagement solutions to help them communicate better with their customers, The company plans to fuel product development and add features like profile management and machine learning to its solution. The capital will also help Digital Onboarding double its headcount this year.
#1. $75 million, January 23
Headquartered in Lexington, Accent Therapeutics specializes in small-molecule precision cancer therapies. Mirae Asset Capital Life Science led the round of Series C capital that will help Accent advance its lead programs through early clinical development including safety, pharmacokinetics and early efficacy studies.
